{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "e493377181dba6ba8a7a87a759e0df39",
    "title": "Morgan Stanley | RESEARCH",
    "source_uri": "2025-08-29/Eli Lilly Co. MounjaroZepbound Script TrackerEli Lilly Co. MounjaroZepbound Script Tracker_2025-08-29",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-27T00:47:58.940776",
      "extracted_at": "2025-10-27T00:47:58.940782"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 29,
        "successful_pages": 29,
        "date": "2025-08-29",
        "publication": "2025-08-29",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 3,
          "removed_paragraphs": 0,
          "reduction_ratio": 0.016926614677064578
        },
        "input_relative_path": "2025-08-29"
      }
    }
  },
  "passages": [
    {
      "passage_id": "dd0171b1b6bd9777",
      "text": "August 29, 2025 11:00 AM GMT",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ee0f098ac73f0fb4",
      "text": "Eli Lilly & Co. | North America",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "cc9aecd9677185f8",
      "text": "Mounjaro TRx/NRx scripts for the week of 8/22/2025 were \\~630,200/321,100 (vs. \\~621,400/315,900 last week) per IQVIA data. Zepbound TRx/NRx scripts were \\~415,900/275,600 (vs. \\~414,400/276,500 last week). We see \\~9% upside to 2025 M+Z sets.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "4f29a9163575150c",
      "text": "We are monitoring the launch of LLY's Mounjaro (tirzepatide) for type 2 diabetes (T2D), and Zepbound (tirzepatide) for obesity given these are the company's key product cycles. Total GLP- 1 TRx (LLY+Novo) grew \\~31% yoy (see Exhibit 14 within). We are focused on Mounjaro+Zepbound impact on overall growth of the GLP- 1 category (see Exhibit 11 within) and share dynamics (Exhibit 16). Total LLY GLP- 1 franchise (Mounjaro+Trulicity+Zepbound) weekly NRx market share was \\~60% (vs. \\~60% last week) - see Exhibit 23 within.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "c7367a86377fcf78",
      "text": "Mounjaro+Trulicity+Zepbound TRx for the current week are \\~1,201,600 vs. \\~1,189,800 the prior (+1.0% w/w). Mounjaro+Zepbound TRx for the current week are \\~1,046,100 vs. \\~1,035,800 the prior (+1.0% w/w). Zepbound vials: there were \\~110,900 vial scripts (vs. \\~113,100 week of 8/15 and 110,890 (restated from 40) week of 8/8).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "f21eb85a6e037285",
      "text": "On August 14, IQVIA reported that data for Zepbound vial volumes would be understated for the week of 8/8/25, as one retail supplier experienced reporting issues and was imputed; IQVIA is working with the supplier to receive missing data and will provide updates as more information becomes available. On August 28, IQVIA gave the estimate for understated TRx/NRx and we have updated our database for the same. We await final update from IQVIA when they will release data for week ending 10/3/25.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d65dcfa5d4e0d986",
      "text": "We recently hosted meetings with LLY mgmt (CEO, CSO, CFO, heads of international, neurology and oncology) at the company's headquarters and we recap our key takeaways HERE.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "3fdc34e8e68a8148",
      "text": "Exhibit 1: Weekly TRx comparison",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "15f595280328988d",
      "text": "medical exemption to stay on Zepbound, including \\(\\sim 20\\%\\) who previously received Wegovy). Within GLP- 1s for obesity only Zepbound NRx share were flat at \\(\\sim 61\\%\\) and Wegovy at \\(\\sim 39\\%\\) (see above and Exhibit 13 for TRx share). We previously lowered our Zepbound 3Q volume estimates to account for this dynamic.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "b01dd165e544e9e0",
      "text": "Per Novo IR - As of July 25 (effective July 18), GLP- 1 prescriptions through NovoCare Pharmacy are included in the weekly US retail prescription statistics provided by IQVIA. Data are included in TRx numbers only and not updated with retroactive effect. Novo also reported that Wegovy cash pay scripts represents \\(\\sim 12\\%\\) of total scripts (or \\(\\sim 31k\\) TRx scripts).",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "f26f226bb4ffe47a",
      "text": "Zepbound vials: In Aug 2024 in the US, LLY launched via LillyDirect (fulfilled through Gifthealth) a vial presentation of Zepbound (single use vials at 2.5/5mg dose) vs. the existing auto- injector pen presentation (doses 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg; Exhibit 18 & Exhibit 25 within). On 2/25/25 LLY expanded the vial offering to include 7.5mg/10mg doses (see HERE) and announced new prices on vials - 2.5mg (\\$349/month), 5mg (\\$499/month), 7.5mg/10mg (\\$499/month). On 6/16/2025 LLY again expanded the vial offering to include 12.5mg/15mg (\\$499/month), and HC providers can begin prescribing the new vial strengths on July 7 and shipments to patients will begin in early August (LINK). With the addition of these doses, every strength of Zepbound vial will be available for \\$499/month or less (\\$349 for the 2.5 mg starter dose) to any eligible adult with obesity and a valid prescription, regardless of insurance.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "11c3f2a567b1b3f5",
      "text": "LLY has previously noted that Tirzepatide scripts (including vials) via LillyDirect (fulfilled through Amazon or Truepill) may not be fully captured in IQVIA data. LLY's understanding, however, is that IQVIA does use a methodology to estimate those scripts. We note that IQVIA disclosed on 2/20/25 that one retail supplier's data restriction for Zepbound was lifted as of the week ending 2/14/25 (Exhibit 30). Per LLY IR, this update means that IQVIA will begin the process to include Zepbound vials from Lilly Direct. Recall, on 12/11/24 LLY and Ro (private) announced a partnership (link) whereby Zepbound vials (link) will be available for patients receiving a prescription from a Ro- affiliated provider, through an integration between Ro and LillyDirect; this has no impact on the price of Zepbound. Separately, TDOC (not covered) announced on 3/6/25 a pharmacy integration agreement with LLY's LillyDirect pharmacy partner (Gifthealth) that will help members without insurance coverage for GLP- 1s for obesity have more seamless access to Zepbound vials (LINK).",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "efb5290e1b0e5e39",
      "text": "Novo announced the launch of NovoCare Pharmacy on 3/5/25 (LINK), which will provide self- pay option of the Wegovy pen for \\$499/month for uninsured patients or eligible patients with commercial insurance who do not have coverage for obesity medicines. This is similar to LLY's LillyDirect offering of Zepbound vials (above). The Novo release also mentioned that over 55mn people in the US have coverage specifically for weight management medicines, and 90% of Wegovy patients with coverage pay \\$0 to \\$25 a month for Wegovy. On 3/24/25, Novo also extended the same benefit to local pharmacies for all eligible cash- paying patients, highlighting that is another avenue for patients to get access to branded product (LINK). On 8/18/25, Novo extended its offering of Ozempic to self- paying, eligible patients with type 2 diabetes at a price of \\$499/month; additionally, Novo",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "d5da0add42d065f0",
      "text": "entered into a collaboration with GoodRx to offer both Generic and Wegovy through the GoodRx platform, making them accessible to self- paying patients.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "bf513c86b907bd40",
      "text": "LLY announced on 8/14 that it will raise the UK list price for Mounjaro effective Sept 1 to align with pricing across Europe and, it's developed markets (see LINK and LINK). LLY IR noted that the NHS- agreed price will remain unchanged; however, list prices to pharmacies will increase across all doses, resulting in higher out- of- pocket costs for private patients. Per news report the increase in prices could range from \\(\\sim 30\\%\\) for lower doses to \\(>100\\%\\) for higher strengths. The adjustment follows a pricing review that initially set the UK launch price lower to support early access during global GLP- 1 supply constraints; with broader availability and stronger clinical validation, LLY is now aligning prices internationally. The change aims to reduce the risk of UK supply being exported to higher- priced markets, support fair contribution toward ongoing R&D investment, and ensure consistent global access.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "1d7c67b271a35e34",
      "text": "GLP- 1 pricing dynamics in obesity are also in focus following CVS/Caremark's announced partnership with Novo on May 1 to significantly increase access to Wegovy for its members at a more affordable price access (LINK). The company is taking a formulary action on July 1 to prefer Wegovy for its members (per LLY, this would impact \\(\\sim 200k\\) Zepbound patients, but some of them could elect to pursue a medical exemption to stay on Zepbound, including \\(\\sim 20\\%\\) who previously received Wegovy). Separately, Cigna/Evernorth announced on May 22 a new benefit option capping patient co- pays at \\(\\$ 200\\) per month on both LLY's Zepbound and Novo's Wegovy and maintaining its less exclusionary approach - see HERE. This strategy deviates significantly from the CVS/Caremark approach above. We previously connected with LLY IR on the Cigna/Evernorth news (see HERE) who noted: (1) it's an open access agreement, which is aligned with the company's contracting strategy (as discussed on their IQ call - see HERE), (2) the first part of the agreement is that Cigna is advertising a new offering (\\$200 co- pay cap plan) as a way for employers to opt- in to obesity coverage at a lower cost to employers. There is an employer/Cigna cost on top of the \\$200 patient co- pay, (3) the second part of the agreement is open access for Zepbound and Wegovy into 2026 on the basic template lives managed by ESI. LLY will not provide further details here, but noted that the impact on pricing is aligned with the company's expectations, and (4) there are no changes to the company's 2025 portfolio pricing guidance of mid- to- high single digit price decline. Novo indicated on 7/29/25 that the company's recent guidance cut was not driven by any changes on GLP- 1 pricing projections (see our note HERE).",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "f1dab02c50e473f0",
      "text": "GLP- 1 compounding: HERE we discuss potential scenarios for GLP- 1 compounding after May 22 (the date after which bulk compounding of Novo's Semaglutide is no longer legally permitted), which essentially hinge on how aggressive Novo chooses to be with respect to pursuing potential legal actions against the compounders. Per Novo, its market research indicates that \\(\\sim 3\\) mn US patients are on a GLP- 1 for obesity, of which 1mn+ are on a compounded product (70% of which is compounded Semaglutide). Novo reiterated this 1mn+ estimate on 7/29/25 (see our note HERE). Our Morgan Stanley HC Technology team visited two compounding pharmacies in NY - see their takeaways HERE.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "dad5d22ecc812542",
      "text": "We believe we are at an inflection point for \"The Broadening\" of GLP- 1 use, which will extend beyond US- based early adopters to date, to larger numbers of",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "ffca7f6062c6b249",
      "text": "patients globally. We project a peak obesity TAM of \\(\\sim\\) 150bn in our base case (see HERE). We see five elements that will drive global penetration to our peak estimates: (1) Greater injectable supply availability, (2) Expanded Payer Coverage/ access, (3) Introduction of oral GLP- 1 medications, (4) Clinical Benefits in new diseases, and (5) Advent of next generation molecules as we discuss in depth HERE. GLP- 1 adoption within the eligible obesity population sits at \\(2 - 3\\%\\) in the US (vs. \\(\\sim 15\\%\\) in T2D) and \\(\\sim 1\\%\\) outside US (OUS), vs. our peak estimates of \\(\\sim 20\\%\\) and \\(10\\%\\) penetration, respectively. This obesity penetration figure of \\(\\sim 3\\%\\) is in line with a recent JAMA publication that looked at a nationwide EHR dataset, including 277mn patient records from over 280 US healthcare systems (LINK).",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "595b753975f1810e",
      "text": "Within we include exhibits on weekly prescription volumes and market share for drugs across the GLP- 1 space, as well as LLY supply ramp. We also include our catalyst calendar ( Exhibit 29 ) for key diabesity events for MS covered companies.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "31f9a28e332f8ef3",
      "text": "Novo is covered by Thibault Botherin. CVS and Cigna are covered by Erin Wright. TDOC is not covered; Gifthealth, Ro and Truepill are private; Evernorth is a division of CI.",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "941fdaa367a5d7f7",
      "text": "See Exhibit 2 below for updated Google search trends in the US for relevant GLP- 1 terms. Our takeaway from the data is that while there were initially differences in the recognition of Novo's Ozempic vs. LLY's products, LLY has made notable progress in strengthening its brand recognition, especially Zepbound, where the gap has narrowed since early 2025.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "178771f404e56123",
      "text": "Exhibit 2: US GLP-1 Google Search Trends",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "304418cd27a1cdd4",
      "text": "Source: Google Trends, MS Research; data are benchmarked to the most active week of the most searched term",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "acfad1725ab81531",
      "text": "In the OUS markets, LLY noted that initial reception for recent launches (including Mexico, Brazil, China, and India) has been strong, but commercial activities have been gated to ensure no supply disruptions (LINK). Our takeaways from the Google search data in OUS markets are: 1) Awareness of LLY's Mounjaro typically rises in line with product launch timing. 2) Once launched, Mounjaro often reaches parity with Novo's Ozempic, as observed in Mexico, Brazil, and India. Notably, brand awareness in Brazil was already high prior to launch and accelerated further afterward, surpassing Ozempic/Wegovy in search interest. This suggests to us that LLY could see further acceleration as additional supply becomes available.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "39b1ee4f9dc606dc",
      "text": "For additional GLP- 1 trends in Europe, see our European Pharma team's prior note HERE.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "3f831f6d51cf8e11",
      "text": "Exhibit 3: Google Trends - Spain",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "6d767d361a38a7e9",
      "text": "Source: Google Trends, MS Research; data are benchmarked to the most active week of the most searched term",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "962cab8637c67830",
      "text": "Exhibit 4: Google Trends - Mexico",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "f4932a06dda652a3",
      "text": "Source: Google Trends, MS Research; data are benchmarked to the most active week of the most searched term",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "d32ac29197e31d14",
      "text": "Exhibit 5: Google Trends - India",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "5d09b0be22f11b51",
      "text": "Exhibit 6: Google Trends - Brazil",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "36ef84444b8e460f",
      "text": "Source: Google Trends, MS Research; data are benchmarked to the most active week of the most searched term",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "46ca3b0f574be251",
      "text": "Source: Google Trends, MS Research; data are benchmarked to the most active week of the most searched term",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "1827e2acbda98ead",
      "text": "In response to questions regarding triangulating prescriptions to patients, we have attempted to estimate the number of patients on GLP- 1 drugs currently. Based on recent TRx data, we estimate that \\(\\sim 8.9\\mathrm{mn}\\) people in the US are on GLP- 1s (Exhibit 2), of which \\(\\sim 5.9\\mathrm{mn}\\) are on GLP- 1s indicated for type 2 diabetes (Ozempic/Trulicity/Mounjaro), and \\(\\sim 3\\mathrm{mn}\\) for those approved for obesity (Wegovy/Zepbound). For ease of calculation, we assume each TRx is for a month of therapy and that each patient stays on drug for the entire year (i.e., 12 TRx/patient/year). Novo noted on the company's 4Q24 EPS call on Feb 5 that Wegovy is treating 1.2mn people in the US. LLY's CEO mentioned during an interview on 5/1/25 that there are \\(\\sim 10\\mathrm{mn}\\) people on a GLP- 1 in the US.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "e54bd9123a7ebab4",
      "text": "Exhibit 7: Estimate of current annualized GLP-1 scripts and patients; Zepbound was understated",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "6272a6c48a62327c",
      "text": "Source: MS Research, IQVIA",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "ed85e8715e2d0637",
      "text": "A key area of investor focus has been on LLY's GLP- 1 manufacturing capabilities and the timing and magnitude at which they can expand to meet underlying demand. Based on our work, it appears that LLY's RTP facility is currently annualizing at \\(\\sim 30\\mathrm{mn}\\) TRx out of 30mn peak auto- injector capacity. Although LLY noted on the company's 2Q24 call that recent supply performance has been driven by the totality of the network, rather than solely from RTP, hence this could be an overestimate of the pace of the ramp. As a result, we previously reassessed our auto- injector supply build and include additional fill/finish sites (including National Resilience in Ohio), as well as provide our detailed projection of timing of the potential supply ramp - see HERE. LLY noted that the FDA approved its Concord manufacturing facility (end of Dec '24/early Jan '25), which in our view is a positive and will be another driver of increasing Tirzepatide auto- injector supply this year.",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "ef86960baec62b89",
      "text": "LLY discussed during 3Q22 earnings that they would be bringing on two new facilities (one at the Research Triangle Park, or \"RTP\", and a second in Concord, North Carolina) to expand their autoinjector capacity (device used for Trulicity, Mounjaro US, and Zepbound",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "4820b46285e2247a",
      "text": "US). LLY discussed that the first facility, RTP, would be online in 2H23 and would double its capacity at the time, and that the Concord facility was a similar size to RTP. The RTP facility has been online since Aug. 2023 and LLY confirmed they have met their goal of 2x capacity in 2H23 vs. 3Q22. The Concord facility has been completed and will start shipping product in 2025. We'd also highlight that Indiana's LEAP manufacturing facility (LINK) is scheduled to be completed in 1Q25 - with a focus on API synthesis/gene therapy production. The ConstructionWire data (Exhibit 8) shows smaller footprint manufacturing facilities being planned for new construction/renovation with near/mid-term completions. LLY also announced on 2/26/25 plans to double its US manufacturing investment, which includes 4 new manufacturing sites - see HERE, but unclear at this point how much is for increments vs. other medicines.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "bdab71c092856244",
      "text": "We have estimated (see below and our prior analysis HERE) that LLY's capacity during 3Q22 was \\(\\sim 30m\\) autoinjector TRx, and that it will reach \\(\\sim 90m\\) from bringing the two additional North Carolina facilities online. LLY also announced that it is beginning construction on another new facility in Germany, which it expects be online in 2027 (which could be a similar footprint to RTP/Concord). LLY acquired an injectable manufacturing facility from Nexus Pharmaceuticals (privately held, LINK) in Prairie, WI, which could add an incremental \\(\\sim 10m\\) annual TRx to the company's existing footprint based on our work - see HERE. Further, on Dec. 5 LLY announced (link) a \\(\\) 3bn\\(expansion of their manufacturing facility in Wisconsin. Per the PR, the expansion will increase LLY's injectable manufacturing capabilities to meet demand for diabetes/obesity drugs, as well as future pipeline products. We previously updated our peak injectable capacity estimates, assuming an additional \\~15mn annual TRx that begin to come online by YE28; see Exhibit 10.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "4f545070dcef8c8a",
      "text": "The timing at which the new supply will come online from these facilities (i.e., when they will be producing at levels approaching their full capacity) is uncertain, and we have made our own estimates (shown below). LLY also launched a vial presentation for Zepbound (2.5mg/5mg doses) in Aug 2024, which they expect to have a more material impact in 2025 - see HERE. On 2/25/25, LLY expanded the Zepbound vial offering to include 7.5mg/10mg doses.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "02abfca80b5af8a8",
      "text": "Exhibit 8: LLY's Ongoing/Planned Construction Projects in the U.S.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "f1bf761ce38cbbc6",
      "text": "Title/LocationStage (Start/End)Const. TypeProject Type (Size)Value ($mn)Lilly Medicine FoundryStarts in 4-12 mosNewManuf./Indust./Warehouse (202,147 sq. ft)$25-$100Lebanon, IN7/2025 - 3Q/2027Manuf./Indust./Warehouse (100,000-249,999 sq. ft)$38Lilly Pharma Manf. RenovationEarly ConstructionManuf./Indust./Warehouse (50,000-99,999 sq. ft)$5-$25Delaware Street Industrial Building10/2024 - 4Q/2025RenovationOffice/Research/Techn. (293,000 sq. ft)$700Indianapolis, INPlanningNewMedical$200Lilly Institute for Genetic MedicineCompleted (&amp;lt;6 mos)NewResearch/Techn. (250,000+ sq. ft)$2,100Boston, MA10/2021 - 3Q/2024Eli Lilly and Co. Manufacturing FacilitiesUnder ConstructionNewManuf./Indust./Warehouse (660,000 sq. ft)$1,000Lebanon, IN04/2023 - 1Q/2025The Grounds at ConcordCompleted (&amp;lt;6 mos)NewManuf./Indust./Warehouse/Res./Dev. (800,000 sq. ft)$1,000Concord, NC06/2022 - 2Q/2024Multi-Building Pharma Res./Dev. And Manuf. CampusConstructionNewRes./Techn. (100,000-249,999 sq. ft)&amp;gt;$100Lincoln Township, IN05/2023 - 10/2027Eli Lilly and Co. Pharma Manufacturing FacilityPlanningNewManuf./Indust./Warehouse (100,000-249,999 sq. ft)$25-$100",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "117fd1700dc14f64",
      "text": "Source: ConstructionWire, Morgan Stanley Research, AlphaWise",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "ed8531c020e92c91",
      "text": "At peak, we estimate LLY's current injectable platform (autoinjectors+Kwikpen) can deliver \\(\\sim \\$ 100bn\\) in total sales (obviously \\(\\$ /\\) script is still evolving) and serve the equivalent of \\(\\sim 22mn\\) patients (Exhibit 10). LLY could make future investments to build additional capacity as well. That said, we believe that in order to achieve statin- like penetration levels of the US market (which we believe is attainable), orals will likely be needed given injectable capacity constraints. Please see our deep dive note (HERE) for further detail.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "6650a4e47435a0bb",
      "text": "Outside the US, LLY has launched Mounjaro in certain markets using a syringe/vial presentation, and will be transitioning its OUS markets to its Kwikpen (repurposed from the company's insulin platform) as the device is approved in each geography. We have estimated that Kwikpen could add \\(\\sim 55mn\\) more TRx capacity for OUS markets (Exhibit 9). Kwikpen was approved in the UK, which was its first major market (see our note HERE) and subsequently in the EU (see HERE). Per 2Q24 commentary, the Kwikpen ramp thus far has included UK, Germany, Saudi Arabia and UAE, with a recent approval in Spain. Kwikpen was also recently made available in Australia (link). We have discussed that we see the OUS opportunity as a potential source of underappreciated upside.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "39ecf8a43866c2c8",
      "text": "In conjunction with LLY's 2025 revenue guidance announcement, the company noted that in 1H25 they expect to produce at least \\(60\\%\\) more saleable doses than in 1H24. We estimate that the \\(60\\%\\) saleable doses increase implies \\(\\sim 35mn\\) doses in 1H25 vs. our estimate of \\(41mn\\) , but OUS +vials is a swing factor and for autoinjectors we have TRx growth of \\(\\sim 60\\%\\) in 1H25 vs. 1H24. Further, LLY may have built inventory during 4Q, as they noted 4Q demand came in below their prior projections. See our prior work on LLY's supply ramp in \"Mapping GLP- 1 Supply\".",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "0dd7ea3061d931aa",
      "text": "Exhibit 9: LLY Kwikpen Capacity Estimates TRx in mns",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "80e38885972ec01b",
      "text": "Key AssumptionsUS % of WW Volumes45%Capacity Utilization70%Kwikpen excess capacity for OUS Tirzepatide80%",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "aaab6c2fbc706025",
      "text": "US Insulin Kwikpen Volumes72OUS88WW Kwikpens Sold160WW Capacity @ 100% Utilization229Excess available capacity @ 100% Utilization69Excess Available Capacity for Kwikpens (mn)55Patient capacity (mn)4.6",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "9c3e7816513bb371",
      "text": "Source: MS Research, Company Data, IQVIA",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "738f58c1a4869372",
      "text": "Exhibit 10: Estimated Peak Sales from LLY's incretin injector platform (TRx/people in 000's)",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "468a4dbca7701fc4",
      "text": "LLY peak capacity (MSE)Annual TRx# of people$/scriptSales ($bn)Auto-injectorsBase30,0002,500$450$ 14RTP, NC (Aug 2023)30,0002,500$$ 14National Resilience, OH (2024)50,0004,167$$ 23Concord, NC (4Q24/1Q25)30,0002,500$$ 14Pleasant Prairie, WI (YE25) - Part I10,000833$$ 5Pleasant Prairie, WI (YE28) - Part II15,0001,250$$ 7BSP, Rome (YE25)15,0001,250$$ 7Alzey, Germany (1H27)30,0002,500$$ 14Total auto-injectors210,00017,500$$ 95Kwikpens55,0004,583$200$11Total265,00022,083$$ 106",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "f4dcb67d858a9cfc",
      "text": "As a point of context, AMGN noted that their manufacturing platform will deliver \\(\\sim 43\\) mn auto- injector devices in 2024. We note that many of AMGN's drugs are dosed less frequently than LLY's Tirzepatide (weekly). REGN noted on the company's 2Q25 conference call that Catalent's Indiana fill/finish facility produces 70- 80bn doses each year.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "79bacfee1754668e",
      "text": "Exhibit 11: Weekly GLP-1 TRx for T2D+Obesity (RHS) and % market share for LLY vs. Novo (LHS)",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "457a98ca78613053",
      "text": "Source: Morgan Stanley Research, IQVIA",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "cf1fedad2363c994",
      "text": "Exhibit 12: Weekly GLP-1 TRx for T2D: Mounjaro+Trulicity+Ozempic TRx (RHS) and % market share (LHS)",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "ffdcb996ab6ddd91",
      "text": "Source: Morgan Stanley Research, IQVIA",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "7c4f782404e8f0f2",
      "text": "Exhibit 13: Weekly GLP-1 TRx for Obesity: Wegovy+Zepbound TRx (RHS) and % market share (LHS)",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "c63063fc8cdb01d0",
      "text": "Source: Morgan Stanley Research, IQVIA",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "cf0c97e005970d2c",
      "text": "Exhibit 14: Weekly GLP-1 TRx Growth YoY (and rolling one-year averages for Total GLP-1, LLY and Novo)",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "3df741f74d0cd6ca",
      "text": "\\\\*Wegovy YOY data are choppy due to prior supply issues hence we do not show it separately. Source: Morgan Stanley Research, IQVIA",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "5a7f90faa750e6a8",
      "text": "Exhibit 15: Weekly TRx by GLP-1 product",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "9f877cf4b8d1e482",
      "text": "Source: Morgan Stanley Research, IQVIA",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "ea1a53236c22d276",
      "text": "Exhibit 16: Weekly GLP-1 TRx Share",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "89607ca0ea4803a9",
      "text": "\\\\*Adlyxin, Soliqua, Victoza, Byetta+Bydureon are part of other. Source: Morgan Stanley Research, IQVIA",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "cfa6c916512fe2fe",
      "text": "Exhibit 17: Wegovy TRx by strength",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "15aff21fe048587a",
      "text": "Source: Morgan Stanley Research, IQVIA",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "290c44661754f8f2",
      "text": "Exhibit 18: Zepbound TRx by strength",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "c638272f967a15e2",
      "text": "Source: Morgan Stanley Research, IQVIA",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "c9ef039804c4ba4d",
      "text": "Exhibit 19: Mounjaro TRx by strength",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "0bd56a928dda4e27",
      "text": "Source: Morgan Stanley Research, IQVIA",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "0c29bc5aae7a70f0",
      "text": "Exhibit 20: Qtd Seq TRx Growth",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "d1cfd007b232da17",
      "text": "Source: Morgan Stanley Research, IQVIA",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "ff7d1aeaec9df13e",
      "text": "Exhibit 21: Weekly GLP-1 NRx Growth YoY (and rolling one-year averages for Total GLP-1, LLY and Novo)",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "31984826a137dff5",
      "text": "\\\\*Wegovy YoY data are choppy due to prior supply issues hence we do not show it separately. Source: Morgan Stanley Research, IQVIA",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "354e55234da3d629",
      "text": "Exhibit 22: Weekly NRx by GLP-1 product",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "33e52e5588bf4e17",
      "text": "Source: Morgan Stanley Research, IQVIA",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "fe30e24b910e0bd2",
      "text": "Exhibit 23: Weekly GLP-1 NRx Share",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "96c166fb7dc90611",
      "text": "\\\\*Adlyxin, Soliqua, Victoza, Byetta+Bydureon are part of other Source: Morgan Stanley Research, IQVIA",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "91ff8f230d766a8f",
      "text": "Exhibit 24: Wegovy NRx by strength",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "ab80ba97b1d5090a",
      "text": "Source: Morgan Stanley Research, IQVIA",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "549fa10d462dbb91",
      "text": "Exhibit 25: Zepbound NRx by strength",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "08a1f3447154d4db",
      "text": "Source: Morgan Stanley Research, IQVIA",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "64c3af286aae0603",
      "text": "Exhibit 26: Mounjaro NRx by strength",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "0b519002074ecdbb",
      "text": "Time Zero Launch Comparisons",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "c86e27f4dfc1216d",
      "text": "Exhibit 27: Mounjaro and Zepbound TRx launch trend",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "0b04ab780175d697",
      "text": "Source: Morgan Stanley Research, IQVIA",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "bc05a932c97a1523",
      "text": "Exhibit 28: GLP-1 launches",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "848fb749a8a24337",
      "text": "Source: Morgan Stanley Research, IQVIA",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "2691c0e17c42ce0f",
      "text": "Exhibit 29: MS Diabesity Catalyst Calendar",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "897bee7d1a8e7713",
      "text": "CompanyTimingDrugComparator(s)EventNVO1Q25Sema 2mgHD InsulinPh3 SUSTAIN OPTIMIZE readout - Sema + low dose insulin vs. high-dose insulinNVO1H252.4mg Sema-File for approval in MASH in US/EUNVO1H25CagriSemaCagri/Sema/PlaceboREDEFINE 1 full dataAMGN1H25MarTide (AMG 133)PlaceboFull Ph2 data presentationAMGN1H25MarTide (AMG 133)PlaceboUpdate on Ph1 PK data from extended titration studyLLY1H25Orforglipron (Oral GLP1)PlaceboPh3 in patients with T2D (ACHIEVE-1) full dataNVO2Q/3Q25CagriSema-Ph1 PK data of single vs. dual-chamber deviceLLY3Q25Orforglipron (Oral GLP1)PlaceboPh3 in Obesity (ATTAIN-1)LLY3Q25Orforglipron (Oral GLP1)PlaceboPh3 in Adults with Obesity + Type 2 Diabetes (ATTAIN-2)LLY2H25Orforglipron (Oral GLP1)Insulin GlarginePh3 CV risk non-inferiority study in patients with T2D + Obesity and increased CV Risk (ACHIEVE-4)LLY2H25Orforglipron (Oral GLP1)RybelsusPh3 H2H vs. oral semaglutide in T2D (ACHIEVE-3)LLY2Q/3Q25Orforglipron (Oral GLP1)PlaceboPh3 in T2D patients + insulin glargine +/-metformin +/-SGLT2 (ACHIEVE-5)LLY2H25Eloralntide (amylin agonist)PlaceboPh2 data in obese/overweight patientsAMGN2H25MarTide (AMG 133)PlaceboData from part 2 of Ph2 studyNVO2H25Sema 2.4mgPlaceboPh3 data in early Alzheimer's disease (evoke)NVO2H25Sema 2.4mgPlaceboPh3 data in early Alzheimer's disease (evoke+)NVO2H25CagriSemaCagri/Sema/TirzepatidePh3 CagriSema vs. Zepbound in obesity H2H data (REDEFINE-4)VKTX2H25Oral VK2735PlaceboPh3 obesity (VENTURE-oral) dataLLY2Q25TirzepatideTrulicityPh3 CV outcomes study in T2D - H2H vs. Trulicity (SURPASS CVOT)LLY2Q25MazdutidePlaceboPh2 data in obese/overweight patientsROG2Q25CT-996PlaceboPh1 data in T2DROG2Q25CT-996TBDInitiate Ph2 studies in obese +/-T2DROG2Q25CT-388PlaceboConduct interim analysis on Ph2 study in obese/overweight patients (internal to ROG only, share data in 2026)NVO2Q25amycretin-Update on next steps for oral/SQ development programROG2Q25CT-868PlaceboPh2 data in T1D with obesityAMGN2Q25MarTide (AMG 133)-Further details on Ph3 program dosing/designNVO2Q25CagriSemaPlaceboPh3 full data in obese pts with T2D vs. placebo (REDEFINE-2)LLY4Q25Orforglipron (Oral GLP1)FanxigaPh3 T2D study vs. Fanxiga (ACHIEVE-2)LLY4Q25Retatrutide (GGG)PlaceboPh3 in obesity and osteoarthritis of the knee (TRUMPH-4)GPCRYE25GSBR-1290PlaceboPh3 Obesity DataNVO2H25-1H26CagriSemaCagri/Sema/PlaceboPh3 T2D data (4 studies, REIMAGINE 1-4)NVO2Q25/26CagriSemaCagri/Sema/PlaceboPh2 data in patients with T2D + CKDLLY2Q25-2Q26Orforglipron (Oral GLP1)-FDA filing in diabetes/obesityZEAL2Q25/26Survodutide (GLP1/GCGR)PlaceboPh3 in obesity -T2D (SYNCHRONIZE-1) dataZEAL2Q25/26Survodutide (GLP1/GCGR)PlaceboPh3 in obesity +T2D (SYNCHRONIZE-2) dataZEAL2Q26Survodutide (GLP1/GCGR)PlaceboPh3 CV safety study in obese/overweight (SYNCHRONIZE-CVOT) dataZEAL2Q26Petrelintide (LA amylin)-Initiate Ph3 monotherapy studies in obesity/T2DNVO2Q26CagriSemaCagri/Sema/TirzepatideREIMAGINE 5 Ph3 data - 1mg Cagri vs. 5mg TirzepatideROG2Q26CT-388PlaceboDisclose Ph2 final data in obese/overweight ptsLLY2Q26High Dose TirzepatidePlaceboPh2 data exploring higher doses of tirzepatide in patients with T2D + obesityLLY2Q26OrforglipronPlaceboPh3 ATTAIN-MAINTAN trial of orfor as maintenance therapy in obese patientsLLY2Q26OrforglipronPlaceboPh3 study in obesity+OSA (ATTAIN-OSA)LLY2Q26TirzepatidePlaceboPh3 SURMOUNT-MAINTAN data - evaluating maintenance of weight loss at 5mg dose vs. maximum tolerated doseLLY2Q26Retatrutide (GGG)PlaceboPh3 Obesity, obesity + osteoarthritis, and obesity + obstructive Sleep apnea (TRUMPH-1) dataLLY2Q26Retatrutide (GGG)PlaceboPh2 on renal function in pts with obesity + chronic kidney disease w/ or w/out T2DLLY2Q26TirzepatidePlaceboPh2 in patients with obesity and CKD with or without T2D (TREASURE-CKD)LLY2Q26TirzepatidePlaceboPh3 study for maintenance of body weight reduction (SURMOUNT-MAINTAN)LLY2Q26Retatrutide (GGG)PlaceboPh3 obesity + diabetes (TRUMPH-2) dataLLY2Q26Retatrutide (GGG)PlaceboPh3 obesity + cardiovascular disease (TRUMPH-3) dataLLY2Q26Retatrutide (GGG)-FDA filing in obesityNVO2Q26Sema 2.4mgPlaceboPh2 data evaluating effect on post smoking cessation weight managementNVO2Q27CagriSemaCagri/Sema/PlaceboPh3 CV non-inferiority/superiority study in obese patients non-T2D and T2D patients (REDEFINE 3)LLY2Q27TirzepatidePlaceboPh3 reduction in risk of morbidity/mortality in obesity (SURMOUNT-MMO) dataNVO2Q27Sema 1mg injPlaceboFOCUS Ph3 data in diabetic retinopathyLLY2Q29Retatrutide (GGG)PlaceboTRUMPH-OUTCOMES (CV outcomes study) readoutNVO2Q32Sema 2.4mg-SELECT-LIFE study completion - periodic data disclosures expected throughout 2020s",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "827b7a55f2e10bef",
      "text": "Source: Morgan Stanley Research",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "f602d917f699163b",
      "text": "Exhibit 30: IQVIA Zepbound Reporting Disclosure",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "53efd76276e329ec",
      "text": "Confidential - For Client's internal Use Only. The data, information, and analysis contained in this document is proprietary to IQVIA and is IQVIA Confidential Information to be used and treated in accordance with the terms of the Licensing and Services Agreement (LSA). Without limiting the foregoing, the data, information, and analysis in this document shall not be shared with any third party except as permitted under the LSA and shall only be used for Client's internal direct benefit.",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "c6da7796819c4cc7",
      "text": "Source: Company Data",
      "page": 20,
      "section": null
    },
    {
      "passage_id": "8010e12a4e656cb2",
      "text": "ChannelsNPA (National Prescription Audit) Monthly and WeeklyNSP (National Sales Perspectives)Chain Pharmacies**Independent Pharmacies**MassMerchandisers(grouped w/Chain Pharmacies)**Foodstores w/Pharmacies**Mail Service Providers**Long-Term Care**HMOs*Non-federal Hospitals*Federal Facilities*Clinics*Home Healthcare*Miscellaneous - Prisons, Universities, Veterinarians*",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "825ea8cb730ce5c5",
      "text": "Monthly TRx (NPA) and Sales (NSP) channel sources",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "73a1a23103b1796f",
      "text": "**TRx** represents total prescriptions dispensed including refills.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "d0c45c5cbab21721",
      "text": "**NRx** represents new prescriptions including renewals and excluding refills, so it does not represent new patient starts. Renewals are the scripts patients get to continue the drug when they run out of refills.",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "2fe68175b1820d7c",
      "text": "**NPA:** \"National estimates of prescriptions, or the rate at which drugs move out of the pharmacy and into the hands of a consumer via formal dispensed prescriptions\".",
      "page": 21,
      "section": null
    },
    {
      "passage_id": "69d7ccef1d8dd735",
      "text": "Morgan Stanley is acting as financial advisor to Scorpion Therapeutics, Inc. (\"Scorpion\") in connection with its definitive agreement for Eli Lilly and Company to acquire Scorpion's PI3Ka inhibitor program STX- 478, as announced on January 13, 2025. The transaction is subject to customary closing conditions. Scorpion has agreed to pay fees to Morgan Stanley for its financial services, including transaction fees that are contingent upon the consummation of the transaction. Please refer to the notes at the end of the report.",
      "page": 22,
      "section": null
    },
    {
      "passage_id": "554aae632b55d644",
      "text": "Our 12- month price target of \\(\\) 1,028\\(is based on a\\) 26x P/E multiple applied to our 3Q26 - 2Q27 EPS estimate of\\) \\ \\(39.53\\) . This multiple is above LLY's 10- year average (28x) and the industry ( \\(\\sim 15x\\) ) but deserved in our view, given the company's growth profile and pipeline optionality.",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "c7343a742a870d2a",
      "text": "Orforglipron outperforms expectations in clinical trials/commercially Tirzepatide has positive outcomes trials in obesity, opens new market LLY brings on autoinjector supply quicker than our expectations",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "20ba5818190de730",
      "text": "Orforglipron is discontinued prior to reaching the market Tirzepatide underperforms obesity expectations Competitor data from diabesity pipeline drugs",
      "page": 23,
      "section": null
    },
    {
      "passage_id": "7380d8e79caf5a74",
      "text": "The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. LLC, and/or Morgan Stanley C.T.V.M. S.A., and/or Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., and/or Morgan Stanley Canada Limited. As used in this disclosure section, Morgan Stanley includes Morgan Stanley & Co. LLC, Morgan Stanley C.T.V.M. S.A., Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., Morgan Stanley Canada Limited and their affiliates as necessary.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "2fd8df9759bd534c",
      "text": "For mportant dislures, stck price chrt and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "5f657100c56d9eaa",
      "text": "For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303- 2495; Hong Kong +852 2848- 5999; Latin America +1 718 754- 5444 (U.S.); London +44 (0)20- 7425- 8169; Singapore +65 6834- 6860; Sydney +61 (0)2- 9770- 1505; Tokyo +81 (0)3- 6836- 9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "eb6889aafd05ce77",
      "text": "Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflict policies. A Portuguese version of the policy can be found at www.morganstanley.com.br",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "0a811b28f6512607",
      "text": "As of July 31, 2025, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: Abbvie Inc., Bristol Myers Squibb Co, Eli Lilly & Co., Johnson & Johnson, Merck & Co., Inc., Organon & Co., Pfizer Inc, Royalty Pharma Plc.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "0d3a4d5907d49ffe",
      "text": "Within the last 12 months, Morgan Stanley managed or co- managed a public offering (or 144A offering) of securities of Abbvie Inc., Eli Lilly & Co., Pfizer Inc.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "02b0bf863310c6aa",
      "text": "Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Abbvie Inc., Bristol Myers Squibb Co., Eli Lilly & Co., Merck & Co., Inc., Pfizer Inc, Royalty Pharma Plc.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "e5813d8be430eb9d",
      "text": "In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Abbvie Inc., Bristol Myers Squibb Co., Eli Lilly & Co., Johnson & Johnson, Merck & Co., Inc., Organon & Co., Pfizer Inc, Royalty Pharma Plc.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "ae40b7bd9ba8f6e2",
      "text": "Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from Abbvie Inc., Bristol Myers Squibb Co., Eli Lilly & Co., Johnson & Johnson, Merck & Co., Inc., Organon & Co., Pfizer Inc, Royalty Pharma Plc.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "b0fb81a49d241f91",
      "text": "Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Abbvie Inc., Bristol Myers Squibb Co., Eli Lilly & Co., Johnson & Johnson, Merck & Co., Inc., Organon & Co., Pfizer Inc, Royalty Pharma Plc.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "6254cc2f18fae385",
      "text": "Within the last 12 months, Morgan Stanley has either provided or is providing non- investment banking, securities- related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: Abbvie Inc., Bristol Myers Squibb Co., Eli Lilly & Co., Johnson & Johnson, Merck & Co., Inc., Organon & Co., Pfizer Inc, Royalty Pharma Plc.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "ae6ca2728da23c55",
      "text": "An employee, director or consultant of Morgan Stanley is a director of Merck & Co., Inc. This person is not a research analyst or a member of a research analyst's household.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "0513520edb190398",
      "text": "The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "a1d90acda356d810",
      "text": "Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "5872f9a5475f3b21",
      "text": "Certain disclosures listed above are also for compliance with applicable regulations in non- US jurisdictions.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "07d6c8d3850ae053",
      "text": "Morgan Stanley uses a relative rating system using terms such as Overweight, Equal- weight, Not- Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal- weight, Not- Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "8ab427702a0d7cad",
      "text": "(as of July 31, 2025)",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "92c2ebfeab6c0ae6",
      "text": "The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm. For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal- weight, Not- Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal- weight, Not- Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal- weight and Not- Rated to hold and Underweight to sell recommendations, respectively.",
      "page": 24,
      "section": null
    },
    {
      "passage_id": "36108f5742767cf1",
      "text": "Coverage UniverseInvestment Banking Clients (IBC)Other Material Investment Services Clients (MISC)Stock Rating CategoryCount% of TotalCount% of Total IBC% of Rating CategoryCount% of Total Other MISCOverweight/Buy149540%37845%25%70141%Equal-weight/Hold160743%37445%23%76645%Not-Rated/Hold50%00%0%20%Underweight/Sell58816%8310%14%23614%Total3,6958351705",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "a9c0f6a6027372f6",
      "text": "Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the % of total' column may not add up to exactly 100 percent.",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "05546a309715349e",
      "text": "Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "2bd88278047deeba",
      "text": "Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "62db32adbb9affb9",
      "text": "Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "41f27581afd9fd67",
      "text": "Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "a04503622a7aec3d",
      "text": "Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "2a7c0fe556e710e9",
      "text": "Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "809d5afc1f06a45f",
      "text": "In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia -relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.",
      "page": 25,
      "section": null
    },
    {
      "passage_id": "c8e0d6ddb5d44b23",
      "text": "A member of Research who had or could have had access to the research prior to completion owns securities (or related derivatives) in the Eli Lilly & Co. This person is not a research analyst or a member of research analyst's household.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "7f5e5c163a0b9b94",
      "text": "Morgan Stanley Research policy is to update research reports and as when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "e32d1af5b5a1ff79",
      "text": "Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "3ea4410a69ea2897",
      "text": "Morgan Stanley produces an equity research product called a \"Tactical Idea.\" Views contained in a \"Tactical Idea\" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "dd319a3b0a8286f5",
      "text": "Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "31426bdfe3b9e8c8",
      "text": "Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (http://www.morganstanley.com/terms.html). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (http://www.morganstanley.com/terms.html). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html). If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research.",
      "page": 26,
      "section": null
    },
    {
      "passage_id": "134bbaac8575b43f",
      "text": "Morga  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t  t  t  t  th  t  t  t  t  t  t  t  t  t  t  e  t  t  t  t  t  t",
      "page": 27,
      "section": null
    },
    {
      "passage_id": "78970de0efbdc646",
      "text": "The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA) or by Morgan Stanley & Co. International plc (ADGM Branch), regulated by the Financial Services Regulatory Authority Abu Dhabi (the FSRA), and is directed at Professional Clients only, as defined by the DFSA or the FSRA, respectively. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria of a Professional Client. A distribution of the different MS Research ratings or recommendations, in percentage terms for Investments in each sector covered, is available upon request from your sales representative.",
      "page": 28,
      "section": null
    },
    {
      "passage_id": "36f5dc454b3894d1",
      "text": "The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.",
      "page": 28,
      "section": null
    },
    {
      "passage_id": "5fce867f137c2690",
      "text": "As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.",
      "page": 28,
      "section": null
    },
    {
      "passage_id": "3ba537b620d1d9f6",
      "text": "The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.",
      "page": 28,
      "section": null
    },
    {
      "passage_id": "3d4739bc30be6eee",
      "text": "Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley. Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework. The issuers and/or fixed income products recommended or discussed in certain fixed income research reports may not be continuously followed. Accordingly, investors should regard those fixed income research reports as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or individual fixed income products. Morgan Stanley may hold, from time to time, material financial and commercial interests regarding the company subject to the Research report.",
      "page": 28,
      "section": null
    },
    {
      "passage_id": "531fe5391aaaf522",
      "text": "Registration granted by SEBI and certification from the National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.",
      "page": 28,
      "section": null
    },
    {
      "passage_id": "13df0f7f4ac96f87",
      "text": "COMPANY (TICKER)RATING (AS OF)PRICE* (08/28/2025)Terence C Flynn, Ph.D.Abbvie Inc. (ABBV.N)O (05/11/2020)$207.92Bristol Myers Squibb Co (BMY.N)U (04/06/2022)$46.88Eli Lilly &amp;amp; Co. (LLY.N)O (09/03/2020)$731.96Johnson &amp;amp; Johnson (JNJ.N)E (09/07/2021)$175.45Merck &amp;amp; Co., Inc. (MRK.N)E (09/07/2021)$83.21Organon &amp;amp; Co. (OGN.N)E (06/11/2021)$9.18Pfizer Inc (PFE.N)E (07/30/2019)$24.60Royalty Pharma Plc (RPX.N)O (05/16/2025)$35.62",
      "page": 28,
      "section": null
    },
    {
      "passage_id": "5039011c231898e6",
      "text": "Stock Ratings are subject to change. Please see latest research for each company. \\\\* Historical prices are not split adjusted.",
      "page": 28,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "5dc8f59a60c48918",
      "name": "ADGM Branch",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "605aa499dd967d64",
      "name": "AM GMT\n\nEli Lilly & Co",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "4a4bef43c7bfa9f1",
      "name": "Abbvie Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ed49291dd8535b70",
      "name": "Abu Dhabi",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "16c8927e95b79ca5",
      "name": "Additional Exhibits",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "eaf08002b00380b0",
      "name": "Although LLY",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a9935cd77e910646",
      "name": "America Index",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e8600890357193e9",
      "name": "Analyst Industry",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "264f4569dd91d68d",
      "name": "Analyst Stock",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7a3a1ee114365837",
      "name": "And Manuf",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f8b9f4a4de87650e",
      "name": "Annual TRx",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2ebc1f6a39f03ec8",
      "name": "Asia Pacific",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d6835c5eb5600b44",
      "name": "Bristol Myers",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2186995778af7f13",
      "name": "Bristol Myers Squibb Co",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "dfa131124eda796d",
      "name": "Building Pharma",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "b0e46a2c6099efe6",
      "name": "CV Risk",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "bf97c7f0a3524745",
      "name": "Canada Limited",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f65cfb198aabe08c",
      "name": "Capacity Estimates",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "18855727cb1fb047",
      "name": "Capacity Utilization",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "98bf4640b315d632",
      "name": "Capital Markets",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "line",
        "title": null,
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "12/26/2021",
              "2/13/2022",
              "4/3/2022",
              "5/22/2022",
              "7/10/2022",
              "8/28/2022",
              "10/16/2022",
              "12/4/2022",
              "1/22/2023",
              "3/12/2023",
              "4/30/2023",
              "6/18/2023",
              "8/6/2023",
              "9/24/2023",
              "11/12/2023",
              "12/31/2023",
              "2/18/2024",
              "4/7/2024",
              "5/26/2024",
              "7/14/2024",
              "9/1/2024",
              "10/20/2024",
              "12/8/2024",
              "1/26/2025",
              "3/16/2025",
              "5/4/2025",
              "6/22/2025",
              "8/10/2025"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 120
            }
          }
        },
        "series": [
          {
            "name": "Ozempic",
            "unit": null,
            "values": [
              1,
              1,
              1,
              1,
              1,
              1,
              2,
              3,
              4,
              6,
              7,
              8,
              9,
              11,
              13,
              15,
              17,
              19,
              21,
              23,
              25,
              98,
              30,
              35,
              38,
              42,
              45,
              48
            ]
          },
          {
            "name": "Wegovy",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              25,
              10
            ]
          },
          {
            "name": "Mounjaro",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              20,
              50,
              30,
              35
            ]
          },
          {
            "name": "Tirzepatide",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Glp1",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          }
        ],
        "figure_id": "6f903723c7ec7a6c",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 11,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "1/27/2017",
              "4/19/2018",
              "7/10/2019",
              "9/29/2020",
              "12/29/2021",
              "3/12/2023",
              "6/1/2024",
              "8/22/2025"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 100
            }
          }
        },
        "series": [
          {
            "name": "Novo GLP-1 franchise % share (T2D+Obesity)",
            "unit": "%",
            "values": [
              48,
              45,
              43,
              42,
              43,
              45,
              48,
              50,
              52,
              54,
              56,
              55,
              53,
              50,
              48,
              45,
              43,
              40,
              38,
              35,
              33,
              30,
              28,
              25,
              23,
              20,
              18,
              15,
              13,
              10,
              8,
              5,
              3,
              0
            ]
          },
          {
            "name": "LLY GLP-1 franchise % share (T2D+Obesity)",
            "unit": "%",
            "values": [
              34,
              37,
              40,
              42,
              43,
              44,
              45,
              46,
              47,
              48,
              49,
              50,
              51,
              52,
              53,
              54,
              55,
              56,
              57,
              58,
              59,
              60,
              61,
              62,
              63,
              64,
              65,
              66,
              67,
              68,
              69,
              70,
              71,
              72
            ]
          },
          {
            "name": "Total GLP-1 TRx (T2D+Obesity)",
            "unit": "TRx",
            "values": [
              100000,
              200000,
              300000,
              400000,
              500000,
              600000,
              700000,
              800000,
              900000,
              1000000,
              1100000,
              1200000,
              1300000,
              1400000,
              1500000,
              1600000,
              1700000,
              1800000,
              1900000,
              2000000,
              2100000,
              2200000,
              2300000,
              2400000,
              2500000,
              2600000
            ]
          }
        ],
        "figure_id": "b9f29767ced4c21f",
        "provenance": {
          "page": 11
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "12/26/2021",
              "2/13/2022",
              "4/3/2022",
              "5/22/2022",
              "7/10/2022",
              "8/28/2022",
              "10/16/2022",
              "12/4/2022",
              "1/22/2023",
              "3/12/2023",
              "4/30/2023",
              "6/18/2023",
              "8/6/2023",
              "9/24/2023",
              "11/12/2023",
              "12/31/2023",
              "2/18/2024",
              "4/7/2024",
              "5/26/2024",
              "7/14/2024",
              "9/1/2024",
              "10/20/2024",
              "12/8/2024",
              "1/26/2025",
              "3/16/2025",
              "5/4/2025",
              "6/22/2025",
              "8/10/2025"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 120
            }
          }
        },
        "series": [
          {
            "name": "Ozempic",
            "unit": null,
            "values": [
              5,
              6,
              8,
              10,
              12,
              13,
              14,
              15,
              20,
              22,
              25,
              28,
              30,
              35,
              40,
              45,
              50,
              55,
              60,
              65,
              70,
              75,
              80,
              85,
              90,
              95,
              100,
              105
            ]
          },
          {
            "name": "Wegovy",
            "unit": null,
            "values": [
              1,
              1,
              1,
              1,
              1,
              1,
              1,
              1,
              2,
              2,
              3,
              4,
              5,
              6,
              7,
              8,
              9,
              10,
              12,
              15,
              18,
              20,
              22,
              25,
              28,
              30,
              32,
              35
            ]
          },
          {
            "name": "Mounjaro",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Tirzepatide",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Glp1",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          }
        ],
        "figure_id": "0c73e8ca633fcaa0",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 21,
        "axes": null,
        "series": [],
        "figure_id": "7d64251924584ac4",
        "provenance": {
          "page": 21
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 5,
        "axes": {
          "x": {
            "type": "datetime",
            "labels": [
              "12/26/2021",
              "2/27/2022",
              "5/1/2022",
              "7/3/2022",
              "9/4/2022",
              "11/6/2022",
              "1/8/2023",
              "3/12/2023",
              "5/14/2023",
              "7/16/2023",
              "9/17/2023",
              "11/19/2023",
              "1/21/2024",
              "3/24/2024",
              "5/26/2024",
              "7/28/2024",
              "9/29/2024",
              "12/1/2024",
              "2/2/2025",
              "4/6/2025",
              "6/8/2025",
              "8/10/2025"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 120
            }
          }
        },
        "series": [
          {
            "name": "Ozempic",
            "unit": null,
            "values": [
              5,
              8,
              10,
              15,
              20,
              25,
              40,
              60,
              70,
              60,
              50,
              70,
              90,
              100,
              80,
              70,
              60,
              65,
              60,
              55,
              50,
              50
            ]
          },
          {
            "name": "Wegovy",
            "unit": null,
            "values": [
              1,
              1,
              2,
              5,
              10,
              15,
              20,
              30,
              35,
              25,
              20,
              15,
              20,
              25,
              20,
              20,
              25,
              30,
              35,
              40,
              45,
              40
            ]
          },
          {
            "name": "Mounjaro",
            "unit": null,
            "values": [
              1,
              1,
              1,
              1,
              5,
              10,
              15,
              20,
              25,
              20,
              18,
              20,
              25,
              30,
              25,
              20,
              20,
              25,
              28,
              25,
              28,
              25
            ]
          },
          {
            "name": "Tirzepatide",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              5,
              10,
              15,
              18,
              20,
              22,
              25,
              28,
              25,
              28,
              25
            ]
          },
          {
            "name": "Zepbound",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          }
        ],
        "figure_id": "f60dd7d6849fc143",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 15,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "7/4/2025",
              "7/11/2025",
              "7/18/2025",
              "7/25/2025",
              "8/1/2025",
              "8/8/2025",
              "8/15/2025",
              "8/22/2025"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": -15,
              "max": 30
            }
          }
        },
        "series": [
          {
            "name": "Ozempic",
            "unit": "%",
            "values": [
              14,
              20,
              20.5,
              20.5,
              20.5,
              21,
              20.5,
              19
            ]
          },
          {
            "name": "Wegovy",
            "unit": "%",
            "values": [
              5,
              11,
              19,
              23,
              24,
              25,
              26,
              27
            ]
          },
          {
            "name": "Trulicity",
            "unit": "%",
            "values": [
              -13,
              -6,
              -4,
              -3,
              -3,
              -3,
              -4,
              -4
            ]
          },
          {
            "name": "Mounjaro",
            "unit": "%",
            "values": [
              5,
              12,
              13,
              14,
              13,
              13,
              13,
              12
            ]
          },
          {
            "name": "Zepbound",
            "unit": "%",
            "values": [
              -2,
              -1,
              -0.5,
              -0.5,
              -1,
              -1,
              -1,
              -2
            ]
          },
          {
            "name": "Total GLP-1",
            "unit": "%",
            "values": [
              0,
              7,
              9,
              9.5,
              9,
              9,
              9,
              9
            ]
          },
          {
            "name": "LLY GLP-1 franchise",
            "unit": "%",
            "values": [
              2,
              6,
              8,
              9,
              9,
              9,
              9,
              9
            ]
          },
          {
            "name": "Novo GLP-1 franchise",
            "unit": "%",
            "values": [
              -5,
              0,
              3,
              5,
              5,
              5,
              5,
              5
            ]
          }
        ],
        "figure_id": "efe7c1e7de502d21",
        "provenance": {
          "page": 15
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 17,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "6/3/2023",
              "11/18/2023",
              "5/3/2023",
              "10/28/2023",
              "4/3/2024",
              "9/28/2024",
              "3/7/2025",
              "6/22/2025"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 70
            }
          }
        },
        "series": [
          {
            "name": "LLY GLP-1 franchise",
            "unit": "%",
            "values": []
          },
          {
            "name": "Novo GLP-1 franchise",
            "unit": "%",
            "values": []
          },
          {
            "name": "Mounjaro",
            "unit": "%",
            "values": []
          },
          {
            "name": "Zepbound total",
            "unit": "%",
            "values": []
          },
          {
            "name": "Ozempic",
            "unit": "%",
            "values": []
          },
          {
            "name": "Wegovy",
            "unit": "%",
            "values": []
          },
          {
            "name": "Trulicity",
            "unit": "%",
            "values": []
          },
          {
            "name": "Rybelsus",
            "unit": "%",
            "values": []
          },
          {
            "name": "Other",
            "unit": "%",
            "values": []
          }
        ],
        "figure_id": "725b7998d69f2e52",
        "provenance": {
          "page": 17
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 18,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "1/5/2024",
              "2/9/2024",
              "3/15/2024",
              "4/19/2024",
              "5/24/2024",
              "6/28/2024",
              "8/2/2024",
              "9/6/2024",
              "10/11/2024",
              "11/15/2024",
              "12/20/2024",
              "1/24/2025",
              "2/28/2025",
              "4/4/2025",
              "5/9/2025",
              "6/13/2025",
              "7/18/2025",
              "8/22/2025"
            ]
          },
          "y": {
            "unit": "NRx",
            "range": {
              "min": 0,
              "max": 100000
            }
          }
        },
        "series": [
          {
            "name": "10MG/0.5ML",
            "unit": "NRx",
            "values": [
              25000,
              30000,
              25000,
              30000,
              20000,
              30000,
              25000,
              20000,
              25000,
              30000,
              35000,
              30000,
              35000,
              40000,
              45000,
              50000,
              55000,
              55000
            ]
          },
          {
            "name": "12.5MG/0.5ML",
            "unit": "NRx",
            "values": [
              15000,
              10000,
              20000,
              10000,
              5000,
              10000,
              20000,
              15000,
              20000,
              25000,
              20000,
              25000,
              25000,
              30000,
              30000,
              35000,
              35000,
              35000
            ]
          },
          {
            "name": "15MG/0.5ML",
            "unit": "NRx",
            "values": [
              35000,
              40000,
              35000,
              40000,
              30000,
              35000,
              30000,
              35000,
              30000,
              35000,
              30000,
              35000,
              35000,
              40000,
              45000,
              50000,
              50000,
              55000
            ]
          },
          {
            "name": "2.5MG/0.5ML",
            "unit": "NRx",
            "values": [
              45000,
              50000,
              40000,
              55000,
              45000,
              50000,
              40000,
              45000,
              40000,
              45000,
              40000,
              45000,
              45000,
              50000,
              55000,
              60000,
              60000,
              65000
            ]
          },
          {
            "name": "5MG/0.5ML",
            "unit": "NRx",
            "values": [
              40000,
              55000,
              65000,
              50000,
              75000,
              60000,
              55000,
              60000,
              55000,
              60000,
              55000,
              60000,
              65000,
              70000,
              75000,
              80000,
              85000,
              80000
            ]
          },
          {
            "name": "7.5MG/0.5ML",
            "unit": "NRx",
            "values": [
              30000,
              35000,
              45000,
              40000,
              55000,
              45000,
              40000,
              45000,
              40000,
              45000,
              40000,
              45000,
              50000,
              55000,
              60000,
              65000,
              65000,
              60000
            ]
          }
        ],
        "figure_id": "8c4f81a9f359a1cc",
        "provenance": {
          "page": 18
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 15,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "1/5/2024",
              "2/9/2024",
              "3/15/2024",
              "4/19/2024",
              "5/24/2024",
              "6/28/2024",
              "8/2/2024",
              "9/6/2024",
              "10/11/2024",
              "11/15/2024",
              "12/20/2024",
              "1/24/2025",
              "2/28/2025",
              "4/4/2025",
              "5/9/2025",
              "6/13/2025",
              "7/18/2025",
              "8/22/2025"
            ]
          },
          "y": {
            "unit": "TRx",
            "range": {
              "min": 0,
              "max": 160000
            }
          }
        },
        "series": [
          {
            "name": "10MG/0.5ML",
            "unit": "TRx",
            "values": [
              45000,
              42000,
              60000,
              40000,
              25000,
              55000,
              65000,
              68000,
              65000,
              70000,
              68000,
              72000,
              75000,
              80000,
              85000,
              90000,
              95000,
              100000
            ]
          },
          {
            "name": "12.5MG/0.5ML",
            "unit": "TRx",
            "values": [
              25000,
              10000,
              20000,
              5000,
              30000,
              10000,
              20000,
              30000,
              40000,
              45000,
              50000,
              55000,
              60000,
              65000,
              70000,
              75000,
              80000,
              85000
            ]
          },
          {
            "name": "15MG/0.5ML",
            "unit": "TRx",
            "values": [
              55000,
              65000,
              45000,
              60000,
              80000,
              60000,
              70000,
              80000,
              75000,
              85000,
              80000,
              88000,
              90000,
              95000,
              100000,
              105000,
              110000,
              115000
            ]
          },
          {
            "name": "2.5MG/0.5ML",
            "unit": "TRx",
            "values": [
              60000,
              50000,
              65000,
              80000,
              30000,
              70000,
              50000,
              60000,
              70000,
              80000,
              60000,
              70000,
              75000,
              80000,
              85000,
              90000,
              95000,
              98000
            ]
          },
          {
            "name": "5MG/0.5ML",
            "unit": "TRx",
            "values": [
              80000,
              90000,
              100000,
              110000,
              90000,
              100000,
              95000,
              105000,
              115000,
              120000,
              110000,
              120000,
              130000,
              135000,
              140000,
              145000,
              150000,
              155000
            ]
          },
          {
            "name": "7.5MG/0.5ML",
            "unit": "TRx",
            "values": [
              70000,
              60000,
              75000,
              65000,
              85000,
              75000,
              85000,
              90000,
              80000,
              95000,
              90000,
              100000,
              105000,
              110000,
              115000,
              120000,
              125000,
              128000
            ]
          }
        ],
        "figure_id": "d9d124a7613a01dc",
        "provenance": {
          "page": 15
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 13,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "6/3/2022",
              "11/18/2022",
              "5/5/2023",
              "10/20/2023",
              "4/5/2024",
              "9/20/2024",
              "3/7/2025",
              "8/22/2025"
            ]
          },
          "y": {
            "unit": "TRx",
            "range": {
              "min": 0,
              "max": 1200000
            }
          }
        },
        "series": [
          {
            "name": "Ozempic",
            "unit": "TRx",
            "values": [
              230000,
              250000,
              450000,
              400000,
              550000,
              600000,
              580000,
              620000
            ]
          },
          {
            "name": "Trulicity",
            "unit": "TRx",
            "values": [
              250000,
              280000,
              280000,
              200000,
              200000,
              180000,
              170000,
              160000
            ]
          },
          {
            "name": "Mounjaro",
            "unit": "TRx",
            "values": [
              0,
              10000,
              200000,
              280000,
              350000,
              450000,
              550000,
              580000
            ]
          },
          {
            "name": "Zepbound",
            "unit": "TRx",
            "values": [
              0,
              0,
              0,
              0,
              100000,
              250000,
              400000,
              450000
            ]
          },
          {
            "name": "Wegovy",
            "unit": "TRx",
            "values": [
              0,
              10000,
              50000,
              100000,
              150000,
              200000,
              250000,
              280000
            ]
          },
          {
            "name": "Mounjaro+Zepbound",
            "unit": "TRx",
            "values": [
              0,
              10000,
              200000,
              280000,
              450000,
              700000,
              950000,
              1050000
            ]
          },
          {
            "name": "Wegovy+Ozempic",
            "unit": "TRx",
            "values": [
              230000,
              260000,
              500000,
              500000,
              700000,
              800000,
              800000,
              850000
            ]
          }
        ],
        "figure_id": "f53e6178f09d4ab9",
        "provenance": {
          "page": 13
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 17,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "1/5/2024",
              "2/9/2024",
              "3/15/2024",
              "4/19/2024",
              "5/24/2024",
              "6/28/2024",
              "8/2/2024",
              "9/6/2024",
              "10/11/2024",
              "11/15/2024",
              "12/20/2024",
              "1/24/2025",
              "2/28/2025",
              "4/4/2025",
              "5/9/2025",
              "6/13/2025",
              "7/18/2025",
              "8/22/2025"
            ]
          },
          "y": {
            "unit": "NRx",
            "range": {
              "min": 0,
              "max": 50000
            }
          }
        },
        "series": [
          {
            "name": "0.25MG/0.5ML",
            "unit": "NRx",
            "values": [
              5000,
              7000,
              12000,
              20000,
              39000,
              35000,
              30000,
              32000,
              18000,
              28000,
              20000,
              24000,
              24000,
              23000,
              24000,
              28000,
              35000,
              31000
            ]
          },
          {
            "name": "0.5MG/0.5ML",
            "unit": "NRx",
            "values": [
              3000,
              4000,
              6000,
              10000,
              20000,
              29000,
              32000,
              30000,
              25000,
              29000,
              24000,
              24000,
              24000,
              24000,
              25000,
              28000,
              34000,
              34000
            ]
          },
          {
            "name": "1.7MG/0.75ML",
            "unit": "NRx",
            "values": [
              2000,
              3000,
              4000,
              6000,
              10000,
              15000,
              20000,
              25000,
              28000,
              27000,
              25000,
              24000,
              24000,
              24000,
              25000,
              28000,
              32000,
              33000
            ]
          },
          {
            "name": "1MG/0.5ML",
            "unit": "NRx",
            "values": [
              7000,
              8000,
              10000,
              13000,
              18000,
              22000,
              28000,
              29000,
              27000,
              29000,
              25000,
              24000,
              24000,
              24000,
              25000,
              28000,
              32000,
              32000
            ]
          },
          {
            "name": "2.4MG/0.75ML",
            "unit": "NRx",
            "values": [
              25000,
              24000,
              23000,
              24000,
              23000,
              25000,
              28000,
              32000,
              35000,
              38000,
              32000,
              31000,
              31000,
              32000,
              34000,
              38000,
              48000,
              44000
            ]
          }
        ],
        "figure_id": "24d048d3ad59db96",
        "provenance": {
          "page": 17
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 14,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "1/5/2024",
              "2/8/2024",
              "3/15/2024",
              "4/18/2024",
              "5/24/2024",
              "6/28/2024",
              "8/2/2024",
              "9/6/2024",
              "10/11/2024",
              "11/15/2024",
              "12/20/2024",
              "1/24/2025",
              "2/28/2025",
              "4/4/2025",
              "5/9/2025",
              "6/13/2025",
              "7/18/2025",
              "8/22/2025"
            ]
          },
          "y": {
            "unit": "TRx",
            "range": {
              "min": 0,
              "max": 90000
            }
          }
        },
        "series": [
          {
            "name": "10MG/0.5ML",
            "unit": "TRx",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "7.5MG/0.5ML",
            "unit": "TRx",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "12.5MG/0.5ML",
            "unit": "TRx",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "5MG/0.5ML",
            "unit": "TRx",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "15MG/0.5ML",
            "unit": "TRx",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "2.5MG/0.5ML",
            "unit": "TRx",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          }
        ],
        "figure_id": "84c7302df625de55",
        "provenance": {
          "page": 14
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "12/26/2021",
              "2/13/2022",
              "4/3/2022",
              "5/22/2022",
              "7/10/2022",
              "8/28/2022",
              "10/16/2022",
              "12/4/2022",
              "1/22/2023",
              "3/12/2023",
              "4/30/2023",
              "6/18/2023",
              "8/6/2023",
              "9/24/2023",
              "11/12/2023",
              "12/31/2023",
              "2/18/2024",
              "4/7/2024",
              "5/26/2024",
              "7/14/2024",
              "9/1/2024",
              "10/20/2024",
              "12/8/2024",
              "1/26/2025",
              "3/16/2025",
              "5/4/2025",
              "6/22/2025",
              "8/10/2025"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 120
            }
          }
        },
        "series": [
          {
            "name": "Ozempic",
            "unit": null,
            "values": [
              18,
              18,
              20,
              22,
              22,
              25,
              28,
              30,
              68,
              35,
              38,
              32,
              30,
              30,
              32,
              55,
              60,
              98,
              55,
              58,
              50,
              80,
              70,
              50,
              40,
              35,
              40,
              45
            ]
          },
          {
            "name": "Wegovy",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              2,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              5,
              10,
              15,
              20,
              25,
              28,
              25,
              20,
              20,
              22,
              20
            ]
          },
          {
            "name": "Mounjaro",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              2,
              0,
              0,
              22,
              0,
              0,
              5,
              10,
              15,
              20,
              25,
              30,
              35,
              40,
              50,
              70,
              90,
              80
            ]
          },
          {
            "name": "Tirzepatide",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Glp1",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          }
        ],
        "figure_id": "737b08670c4d7c81",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 11,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "1/8/2021",
              "9/6/2021",
              "5/5/2022",
              "1/1/2023",
              "8/30/2023",
              "4/27/2024",
              "12/24/2024",
              "8/22/2025"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 80
            }
          }
        },
        "series": [
          {
            "name": "Mounjaro % share (Mounjaro+Trulicity+Ozempic)",
            "unit": "%",
            "values": [
              0,
              0,
              0,
              25,
              30,
              35,
              40,
              45
            ]
          },
          {
            "name": "Mounjaro+Trulicity % share (Mounjaro+Trulicity+Ozempic)",
            "unit": "%",
            "values": [
              62,
              60,
              58,
              50,
              52,
              55,
              57,
              58
            ]
          },
          {
            "name": "Total TRx (Mounjaro+Trulicity+Ozempic)",
            "unit": "TRx",
            "values": [
              200000,
              300000,
              400000,
              800000,
              1000000,
              1200000,
              1400000,
              1500000
            ]
          },
          {
            "name": "Trulicity % share (Mounjaro+Trulicity+Ozempic)",
            "unit": "%",
            "values": [
              null,
              null,
              48,
              35,
              28,
              20,
              15,
              12
            ]
          },
          {
            "name": "Ozempic % share (Mounjaro+Trulicity+Ozempic)",
            "unit": "%",
            "values": [
              38,
              42,
              48,
              45,
              40,
              35,
              30,
              28
            ]
          }
        ],
        "figure_id": "09e5b9fe9f4be252",
        "provenance": {
          "page": 11
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "12/26/2021",
              "2/13/2022",
              "4/3/2022",
              "5/22/2022",
              "7/10/2022",
              "8/28/2022",
              "10/16/2022",
              "12/4/2022",
              "1/22/2023",
              "3/12/2023",
              "4/30/2023",
              "6/18/2023",
              "8/6/2023",
              "9/24/2023",
              "11/12/2023",
              "12/31/2023",
              "2/18/2024",
              "4/7/2024",
              "5/26/2024",
              "7/14/2024",
              "9/1/2024",
              "10/20/2024",
              "12/8/2024",
              "1/26/2025",
              "3/16/2025",
              "5/4/2025",
              "6/22/2025",
              "8/10/2025"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 120
            }
          }
        },
        "series": [
          {
            "name": "Ozempic",
            "unit": null,
            "values": [
              2,
              3,
              4,
              5,
              6,
              7,
              8,
              10,
              12,
              25,
              20,
              28,
              20,
              18,
              22,
              25,
              30,
              35,
              40,
              45,
              55,
              40,
              95,
              45,
              40,
              45,
              55,
              60
            ]
          },
          {
            "name": "Wegovy",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              25,
              35,
              40,
              45
            ]
          },
          {
            "name": "Mounjaro",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              20,
              30,
              50,
              65
            ]
          },
          {
            "name": "Tirzepatide",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              32,
              2,
              1,
              1,
              1,
              1,
              1,
              1,
              2,
              3,
              4,
              5,
              6,
              7,
              8,
              9,
              10,
              11,
              12
            ]
          },
          {
            "name": "Glp1",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          }
        ],
        "figure_id": "7ed27e6f704e2e2e",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 14,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "1/5/2024",
              "2/9/2024",
              "3/15/2024",
              "4/19/2024",
              "5/24/2024",
              "6/28/2024",
              "8/2/2024",
              "9/6/2024",
              "10/11/2024",
              "11/15/2024",
              "12/20/2024",
              "1/24/2025",
              "2/28/2025",
              "4/4/2025",
              "5/9/2025",
              "6/13/2025",
              "7/18/2025",
              "8/22/2025"
            ]
          },
          "y": {
            "unit": "TRx",
            "range": {
              "min": 0,
              "max": 100000
            }
          }
        },
        "series": [
          {
            "name": "0.25MG/0.5ML",
            "unit": "TRx",
            "values": [
              5000,
              8000,
              10000,
              20000,
              40000,
              30000,
              35000,
              38000,
              20000,
              30000,
              32000,
              28000,
              28000,
              30000,
              32000,
              32000,
              40000,
              40000
            ]
          },
          {
            "name": "0.5MG/0.5ML",
            "unit": "TRx",
            "values": [
              2000,
              5000,
              8000,
              12000,
              20000,
              25000,
              30000,
              35000,
              30000,
              35000,
              38000,
              30000,
              30000,
              32000,
              35000,
              40000,
              45000,
              50000
            ]
          },
          {
            "name": "1.7MG/0.75ML",
            "unit": "TRx",
            "values": [
              10000,
              20000,
              22000,
              20000,
              25000,
              30000,
              35000,
              40000,
              45000,
              48000,
              40000,
              38000,
              40000,
              42000,
              45000,
              50000,
              55000,
              55000
            ]
          },
          {
            "name": "1MG/0.5ML",
            "unit": "TRx",
            "values": [
              8000,
              10000,
              15000,
              20000,
              25000,
              30000,
              35000,
              38000,
              40000,
              42000,
              35000,
              32000,
              35000,
              38000,
              40000,
              45000,
              48000,
              50000
            ]
          },
          {
            "name": "2.4MG/0.75ML",
            "unit": "TRx",
            "values": [
              50000,
              52000,
              50000,
              55000,
              60000,
              65000,
              70000,
              75000,
              60000,
              70000,
              80000,
              65000,
              70000,
              72000,
              75000,
              78000,
              90000,
              88000
            ]
          }
        ],
        "figure_id": "573972f4bc9eb773",
        "provenance": {
          "page": 14
        }
      },
      {
        "type": "table",
        "title": "Zepbound Data Reporting Release",
        "page": 21,
        "axes": {},
        "series": [
          {
            "name": "Offering Family",
            "values": [
              "RX",
              "SALES",
              "PATIENT",
              "REFERENCE",
              "MANAGED MARKETS"
            ]
          },
          {
            "name": "Channels",
            "values": [
              "RETAIL",
              "MAIL",
              "LTC",
              "NON-RETAIL"
            ]
          },
          {
            "name": "Data Table Headers",
            "values": [
              {
                "Offering": "NPA, NTB"
              },
              {
                "Weekly (WE)": {
                  "Impacted / Adjusted Time Frame": {
                    "From": null,
                    "To": null
                  },
                  "Go Forward": null,
                  "History Adjustment": null
                }
              },
              {
                "Monthly": {
                  "Impacted / Adjusted Time Frame": {
                    "From": null,
                    "To": null
                  },
                  "Go Forward": null,
                  "History Adjustment": null
                }
              }
            ]
          }
        ],
        "figure_id": "f3ef7e10e86efb74",
        "provenance": {
          "page": 21
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "54a41bf1f762c2fc",
        "value": 0.09,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "A data. Zepbound TRx/NRx scripts were \\~415,900/275,600 (vs. \\~414,400/276,500 last week). We see \\~9% upside to 2025 M+Z sets. We are monitoring the launch of LLY's Mounjaro (tirzepatide) for type 2 ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "55c897169f1aeeea",
        "value": 0.31,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "e) for obesity given these are the company's key product cycles. Total GLP- 1 TRx (LLY+Novo) grew \\~31% yoy (see Exhibit 14 within). We are focused on Mounjaro+Zepbound impact on overall growth of the",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "298f431ac9798d30",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Exhibit 16). Total LLY GLP- 1 franchise (Mounjaro+Trulicity+Zepbound) weekly NRx market share was \\~60% (vs. \\~60% last week) - see Exhibit 23 within. Mounjaro+Trulicity+Zepbound TRx for the current w",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "e14d87bc88ed96a4",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ". Total LLY GLP- 1 franchise (Mounjaro+Trulicity+Zepbound) weekly NRx market share was \\~60% (vs. \\~60% last week) - see Exhibit 23 within. Mounjaro+Trulicity+Zepbound TRx for the current week are \\~1",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "2c9a7033fbd6a46f",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "n. Mounjaro+Trulicity+Zepbound TRx for the current week are \\~1,201,600 vs. \\~1,189,800 the prior (+1.0% w/w). Mounjaro+Zepbound TRx for the current week are \\~1,046,100 vs. \\~1,035,800 the prior (+1.",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "d2888d203004c4ea",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "(+1.0% w/w). Mounjaro+Zepbound TRx for the current week are \\~1,046,100 vs. \\~1,035,800 the prior (+1.0% w/w). Zepbound vials: there were \\~110,900 vial scripts (vs. \\~113,100 week of 8/15 and 110,890",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "2179ed7c4324eb11",
        "value": 0.9,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ned that over 55mn people in the US have coverage specifically for weight management medicines, and 90% of Wegovy patients with coverage pay \\$0 to \\$25 a month for Wegovy. On 3/24/25, Novo also exten",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "3b8e13cefc17a060",
        "value": 349.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "he vial offering to include 7.5mg/10mg doses (see HERE) and announced new prices on vials - 2.5mg (\\$349/month), 5mg (\\$499/month), 7.5mg/10mg (\\$499/month). On 6/16/2025 LLY again expanded the vial o",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "7df45a9490d056be",
        "value": 499.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "include 7.5mg/10mg doses (see HERE) and announced new prices on vials - 2.5mg (\\$349/month), 5mg (\\$499/month), 7.5mg/10mg (\\$499/month). On 6/16/2025 LLY again expanded the vial offering to include 1",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "c257385107b388ac",
        "value": 499.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "(see HERE) and announced new prices on vials - 2.5mg (\\$349/month), 5mg (\\$499/month), 7.5mg/10mg (\\$499/month). On 6/16/2025 LLY again expanded the vial offering to include 12.5mg/15mg (\\$499/month),",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "79543ae55e6993d4",
        "value": 499.0,
        "unit": "$",
        "metric_type": "currency",
        "context": ".5mg/10mg (\\$499/month). On 6/16/2025 LLY again expanded the vial offering to include 12.5mg/15mg (\\$499/month), and HC providers can begin prescribing the new vial strengths on July 7 and shipments t",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "f70801d2e6d8bfac",
        "value": 499.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "st (LINK). With the addition of these doses, every strength of Zepbound vial will be available for \\$499/month or less (\\$349 for the 2.5 mg starter dose) to any eligible adult with obesity and a vali",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "23280da0adc51d54",
        "value": 349.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "ddition of these doses, every strength of Zepbound vial will be available for \\$499/month or less (\\$349 for the 2.5 mg starter dose) to any eligible adult with obesity and a valid prescription, regar",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "c655e66b40f19a77",
        "value": 499.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "h of NovoCare Pharmacy on 3/5/25 (LINK), which will provide self- pay option of the Wegovy pen for \\$499/month for uninsured patients or eligible patients with commercial insurance who do not have cov",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "3bb76b89ac76b6f6",
        "value": 0.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "overage specifically for weight management medicines, and 90% of Wegovy patients with coverage pay \\$0 to \\$25 a month for Wegovy. On 3/24/25, Novo also extended the same benefit to local pharmacies f",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "ea723e4d174db95e",
        "value": 25.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "specifically for weight management medicines, and 90% of Wegovy patients with coverage pay \\$0 to \\$25 a month for Wegovy. On 3/24/25, Novo also extended the same benefit to local pharmacies for all e",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "252c726d70866e01",
        "value": 499.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "nded its offering of Ozempic to self- paying, eligible patients with type 2 diabetes at a price of \\$499/month; additionally, Novo<endofsentence>",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "dca108d2a37920c8",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "t \\(\\sim 3\\) mn US patients are on a GLP- 1 for obesity, of which 1mn+ are on a compounded product (70% of which is compounded Semaglutide). Novo reiterated this 1mn+ estimate on 7/29/25 (see our note",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "2c0cc86dd99d5666",
        "value": 200.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "Separately, Cigna/Evernorth announced on May 22 a new benefit option capping patient co- pays at \\(\\$ 200\\) per month on both LLY's Zepbound and Novo's Wegovy and maintaining its less exclusionary app",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "515d46f16a90671f",
        "value": 200.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "call - see HERE), (2) the first part of the agreement is that Cigna is advertising a new offering (\\$200 co- pay cap plan) as a way for employers to opt- in to obesity coverage at a lower cost to empl",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "313b1c8f4b634c5a",
        "value": 200.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "in to obesity coverage at a lower cost to employers. There is an employer/Cigna cost on top of the \\$200 patient co- pay, (3) the second part of the agreement is open access for Zepbound and Wegovy in",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "519e9b8c032046ad",
        "value": 25.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "tarts in 4-12 mos</td><td rowspan=\"3\">New</td><td>Manuf./Indust./Warehouse (202,147 sq. ft)</td><td>$25-$100</td></tr><tr><td>Lebanon, IN</td><td>7/2025 - 3Q/2027</td><td>Manuf./Indust./Warehouse (100",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "64aaaef2dadba26c",
        "value": 100.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "s in 4-12 mos</td><td rowspan=\"3\">New</td><td>Manuf./Indust./Warehouse (202,147 sq. ft)</td><td>$25-$100</td></tr><tr><td>Lebanon, IN</td><td>7/2025 - 3Q/2027</td><td>Manuf./Indust./Warehouse (100,000",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "5a8791681c45cf90",
        "value": 38.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "anon, IN</td><td>7/2025 - 3Q/2027</td><td>Manuf./Indust./Warehouse (100,000-249,999 sq. ft)</td><td>$38</td></tr><tr><td>Lilly Pharma Manf. Renovation</td><td>Early Construction</td><td>Manuf./Indust.",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "0918c54b01f86545",
        "value": 5.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "novation</td><td>Early Construction</td><td>Manuf./Indust./Warehouse (50,000-99,999 sq. ft)</td><td>$5-$25</td></tr><tr><td>Delaware Street Industrial Building</td><td>10/2024 - 4Q/2025</td><td>Renova",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "67b2dc282ceebad9",
        "value": 25.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "ation</td><td>Early Construction</td><td>Manuf./Indust./Warehouse (50,000-99,999 sq. ft)</td><td>$5-$25</td></tr><tr><td>Delaware Street Industrial Building</td><td>10/2024 - 4Q/2025</td><td>Renovatio",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "7ea460f5108f9645",
        "value": 700.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>10/2024 - 4Q/2025</td><td>Renovation</td><td>Office/Research/Techn. (293,000 sq. ft)</td><td>$700</td></tr><tr><td>Indianapolis, IN</td><td>Planning</td><td>New</td><td>Medical</td><td>$200</td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "350289a9af7161b8",
        "value": 200.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "/td><td>$700</td></tr><tr><td>Indianapolis, IN</td><td>Planning</td><td>New</td><td>Medical</td><td>$200</td></tr><tr><td>Lilly Institute for Genetic Medicine</td><td>Completed (&amp;lt;6 mos)</td><td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "53ef788b26e67b26",
        "value": 2100.0,
        "unit": "$",
        "metric_type": "currency",
        "context": ")</td><td rowspan=\"2\">New</td><td rowspan=\"2\">Research/Techn. (250,000+ sq. ft)</td><td rowspan=\"2\">$2,100</td></tr><tr><td>Boston, MA</td><td>10/2021 - 3Q/2024</td></tr><tr><td>Eli Lilly and Co. Manu",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "d94aa827b135bd6a",
        "value": 1000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "d rowspan=\"2\">New</td><td rowspan=\"2\">Manuf./Indust./Warehouse (660,000 sq. ft)</td><td rowspan=\"2\">$1,000</td></tr><tr><td>Lebanon, IN</td><td>04/2023 - 1Q/2025</td></tr><tr><td>The Grounds at Concor",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "b641b4d84f9c91ab",
        "value": 1000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "\"2\">New</td><td rowspan=\"2\">Manuf./Indust./Warehouse/Res./Dev. (800,000 sq. ft)</td><td rowspan=\"2\">$1,000</td></tr><tr><td>Concord, NC</td><td>06/2022 - 2Q/2024</td></tr><tr><td>Multi-Building Pharma",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "31f35d950ba468dc",
        "value": 100.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "owspan=\"2\">New</td><td rowspan=\"2\">Res./Techn. (100,000-249,999 sq. ft)</td><td rowspan=\"2\">&amp;gt;$100</td></tr><tr><td>Lincoln Township, IN</td><td>05/2023 - 10/2027</td></tr><tr><td>Eli Lilly and ",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "d0080d90cf11fd54",
        "value": 25.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "lity</td><td>Planning</td><td>New</td><td>Manuf./Indust./Warehouse (100,000-249,999 sq. ft)</td><td>$25-$100</td></tr></table> Source: ConstructionWire, Morgan Stanley Research, AlphaWise<endofsent",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "64ddcdad8262a2eb",
        "value": 100.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>Planning</td><td>New</td><td>Manuf./Indust./Warehouse (100,000-249,999 sq. ft)</td><td>$25-$100</td></tr></table> Source: ConstructionWire, Morgan Stanley Research, AlphaWise<endofsentence",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "76f48b2afca06881",
        "value": 100.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "At peak, we estimate LLY's current injectable platform (autoinjectors+Kwikpen) can deliver \\(\\sim \\$ 100bn\\) in total sales (obviously \\(\\$ /\\) script is still evolving) and serve the equivalent of \\(",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "ae6d44efd42e4422",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tes TRx in mns <table><tr><td>Key Assumptions</td><td></td></tr><tr><td>US % of WW Volumes</td><td>45%</td></tr><tr><td>Capacity Utilization</td><td>70%</td></tr><tr><td>Kwikpen excess capacity for OU",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "c6fb7b9007c5d9df",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td></td></tr><tr><td>US % of WW Volumes</td><td>45%</td></tr><tr><td>Capacity Utilization</td><td>70%</td></tr><tr><td>Kwikpen excess capacity for OUS Tirzepatide</td><td>80%</td></tr></table> Kwikp",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "7714ae2b3bb0b418",
        "value": 0.8,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "pacity Utilization</td><td>70%</td></tr><tr><td>Kwikpen excess capacity for OUS Tirzepatide</td><td>80%</td></tr></table> Kwikpen Volumes <table><tr><td>US Insulin Kwikpen Volumes</td><td>72</td></tr>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "bbbac6633781bbad",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<tr><td>OUS</td><td>88</td></tr><tr><td>WW Kwikpens Sold</td><td>160</td></tr><tr><td>WW Capacity @ 100% Utilization</td><td>229</td></tr><tr><td>Excess available capacity @ 100% Utilization</td><td>6",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "d429d16471c91b7f",
        "value": 1.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/tr><tr><td>WW Capacity @ 100% Utilization</td><td>229</td></tr><tr><td>Excess available capacity @ 100% Utilization</td><td>69</td></tr><tr><td>Excess Available Capacity for Kwikpens (mn)</td><td>55<",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "01239d836253479f",
        "value": 450.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "tors</td><td></td><td></td><td></td><td></td></tr><tr><td>Base</td><td>30,000</td><td>2,500</td><td>$450</td><td>$ 14</td></tr><tr><td>RTP, NC (Aug 2023)</td><td>30,000</td><td>2,500</td><td>$</td><td",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "54f20d93add77439",
        "value": 14.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td></td><td></td><td></td></tr><tr><td>Base</td><td>30,000</td><td>2,500</td><td>$450</td><td>$ 14</td></tr><tr><td>RTP, NC (Aug 2023)</td><td>30,000</td><td>2,500</td><td>$</td><td>$ 14</td></t",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "6d42f9fdb3b6bc31",
        "value": 14.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "450</td><td>$ 14</td></tr><tr><td>RTP, NC (Aug 2023)</td><td>30,000</td><td>2,500</td><td>$</td><td>$ 14</td></tr><tr><td>National Resilience, OH (2024)</td><td>50,000</td><td>4,167</td><td>$</td><td>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "71cefadf5665fcbe",
        "value": 23.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "$ 14</td></tr><tr><td>National Resilience, OH (2024)</td><td>50,000</td><td>4,167</td><td>$</td><td>$ 23</td></tr><tr><td>Concord, NC (4Q24/1Q25)</td><td>30,000</td><td>2,500</td><td>$</td><td>$ 14</t",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "7a1a4c823d956838",
        "value": 14.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>$ 23</td></tr><tr><td>Concord, NC (4Q24/1Q25)</td><td>30,000</td><td>2,500</td><td>$</td><td>$ 14</td></tr><tr><td>Pleasant Prairie, WI (YE25) - Part I</td><td>10,000</td><td>833</td><td>$</td>",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "53ade0934e3ea7cd",
        "value": 5.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td></tr><tr><td>Pleasant Prairie, WI (YE25) - Part I</td><td>10,000</td><td>833</td><td>$</td><td>$ 5</td></tr><tr><td>Pleasant Prairie, WI (YE28) - Part II</td><td>15,000</td><td>1,250</td><td>$</t",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "05c2a343bb10beef",
        "value": 7.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "d></tr><tr><td>Pleasant Prairie, WI (YE28) - Part II</td><td>15,000</td><td>1,250</td><td>$</td><td>$ 7</td></tr><tr><td>BSP, Rome (YE25)</td><td>15,000</td><td>1,250</td><td>$</td><td>$ 7</td><td></t",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "aa94f4a1094f3b98",
        "value": 7.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "><td>$</td><td>$ 7</td></tr><tr><td>BSP, Rome (YE25)</td><td>15,000</td><td>1,250</td><td>$</td><td>$ 7</td><td></td></tr><tr><td>Alzey, Germany (1H27)</td><td>30,000</td><td>2,500</td><td>$</td><td>$",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "e945d0ae722fadbd",
        "value": 14.0,
        "unit": "$",
        "metric_type": "currency",
        "context": ">$ 7</td><td></td></tr><tr><td>Alzey, Germany (1H27)</td><td>30,000</td><td>2,500</td><td>$</td><td>$ 14</td></tr><tr><td>Total auto-injectors</td><td>210,000</td><td>17,500</td><td>$</td><td>$ 95</td",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "429e0f44b50c077e",
        "value": 95.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "/td><td>$ 14</td></tr><tr><td>Total auto-injectors</td><td>210,000</td><td>17,500</td><td>$</td><td>$ 95</td></tr><tr><td>Kwikpens</td><td>55,000</td><td>4,583</td><td>$200</td><td>$11</td></tr><tr><t",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "81a32df3a831b9db",
        "value": 200.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "td><td>17,500</td><td>$</td><td>$ 95</td></tr><tr><td>Kwikpens</td><td>55,000</td><td>4,583</td><td>$200</td><td>$11</td></tr><tr><td>Total</td><td>265,000</td><td>22,083</td><td>$</td><td>$ 106</td><",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "ecb7061a0af9e0de",
        "value": 11.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "</td><td>$</td><td>$ 95</td></tr><tr><td>Kwikpens</td><td>55,000</td><td>4,583</td><td>$200</td><td>$11</td></tr><tr><td>Total</td><td>265,000</td><td>22,083</td><td>$</td><td>$ 106</td></tr></table> ",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "e2418e1119aa18e0",
        "value": 106.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "83</td><td>$200</td><td>$11</td></tr><tr><td>Total</td><td>265,000</td><td>22,083</td><td>$</td><td>$ 106</td></tr></table> Source: MS Research As a point of context, AMGN noted that their manufacturi",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "e0e08b9d36dd8dc6",
        "value": 0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Regulatory Disclosures on Subject Companies As of July 31, 2025, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanle",
        "provenance": {
          "page": 24
        }
      },
      {
        "num_id": "ddc1216f8d2cc08e",
        "value": 0.4,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ry</td><td>Count</td><td>% of Total Other MISC</td></tr><tr><td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</",
        "provenance": {
          "page": 25
        }
      },
      {
        "num_id": "b7f94abfdd23d946",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">% of Total Other MISC</td></tr><tr><td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%<",
        "provenance": {
          "page": 25
        }
      },
      {
        "num_id": "301e36df9c4917c5",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Other MISC</td></tr><tr><td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374<",
        "provenance": {
          "page": 25
        }
      },
      {
        "num_id": "2e3bbe2b741c12b8",
        "value": 0.41,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Overweight/Buy</td><td>1495</td><td>40%</td><td>378</td><td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%<",
        "provenance": {
          "page": 25
        }
      },
      {
        "num_id": "2bff4bb2329db4d8",
        "value": 0.43,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>45%</td><td>25%</td><td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td>",
        "provenance": {
          "page": 25
        }
      },
      {
        "num_id": "3d382734b94da0bd",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>701</td><td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td",
        "provenance": {
          "page": 25
        }
      },
      {
        "num_id": "bac1a17a39b74ab2",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>41%</td></tr><tr><td>Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0",
        "provenance": {
          "page": 25
        }
      },
      {
        "num_id": "d543876a900bbc93",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">Equal-weight/Hold</td><td>1607</td><td>43%</td><td>374</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</",
        "provenance": {
          "page": 25
        }
      },
      {
        "num_id": "5bf7bc010c647544",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4</td><td>45%</td><td>23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>58",
        "provenance": {
          "page": 25
        }
      },
      {
        "num_id": "4dd58c48e8d61d62",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">23%</td><td>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td",
        "provenance": {
          "page": 25
        }
      },
      {
        "num_id": "b6141a00b5cfb603",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>766</td><td>45%</td></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td",
        "provenance": {
          "page": 25
        }
      },
      {
        "num_id": "6e16342ed18a67a0",
        "value": 0.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></tr><tr><td>Not-Rated/Hold</td><td>5</td><td>0%</td><td>0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td>",
        "provenance": {
          "page": 25
        }
      },
      {
        "num_id": "021823fecd0e6ea0",
        "value": 0.16,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">0</td><td>0%</td><td>0%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td><td>14%</td></tr><tr><td>Total</td><td>3,695<",
        "provenance": {
          "page": 25
        }
      },
      {
        "num_id": "bc1cea61f61106dc",
        "value": 0.1,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "%</td><td>2</td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td><td>14%</td></tr><tr><td>Total</td><td>3,695</td><td></td><td>835</t",
        "provenance": {
          "page": 25
        }
      },
      {
        "num_id": "b681263efbe07530",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>0%</td></tr><tr><td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td><td>14%</td></tr><tr><td>Total</td><td>3,695</td><td></td><td>835</td><td></td><",
        "provenance": {
          "page": 25
        }
      },
      {
        "num_id": "fca38977bb3fe01c",
        "value": 0.14,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Underweight/Sell</td><td>588</td><td>16%</td><td>83</td><td>10%</td><td>14%</td><td>236</td><td>14%</td></tr><tr><td>Total</td><td>3,695</td><td></td><td>835</td><td></td><td></td><td>1705</td><td",
        "provenance": {
          "page": 25
        }
      },
      {
        "num_id": "767922473d9d278f",
        "value": 207.92,
        "unit": "$",
        "metric_type": "currency",
        "context": "Flynn, Ph.D.</td><td></td><td></td></tr><tr><td>Abbvie Inc. (ABBV.N)</td><td>O (05/11/2020)</td><td>$207.92</td></tr><tr><td>Bristol Myers Squibb Co (BMY.N)</td><td>U (04/06/2022)</td><td>$46.88</td><",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "45a0acfd48b75f08",
        "value": 46.88,
        "unit": "$",
        "metric_type": "currency",
        "context": "20)</td><td>$207.92</td></tr><tr><td>Bristol Myers Squibb Co (BMY.N)</td><td>U (04/06/2022)</td><td>$46.88</td></tr><tr><td>Eli Lilly &amp;amp; Co. (LLY.N)</td><td>O (09/03/2020)</td><td>$731.96</td><",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "706c6eaece87e72b",
        "value": 731.96,
        "unit": "$",
        "metric_type": "currency",
        "context": "022)</td><td>$46.88</td></tr><tr><td>Eli Lilly &amp;amp; Co. (LLY.N)</td><td>O (09/03/2020)</td><td>$731.96</td></tr><tr><td>Johnson &amp;amp; Johnson (JNJ.N)</td><td>E (09/07/2021)</td><td>$175.45</t",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "839ff3568660bae2",
        "value": 175.45,
        "unit": "$",
        "metric_type": "currency",
        "context": ")</td><td>$731.96</td></tr><tr><td>Johnson &amp;amp; Johnson (JNJ.N)</td><td>E (09/07/2021)</td><td>$175.45</td></tr><tr><td>Merck &amp;amp; Co., Inc. (MRK.N)</td><td>E (09/07/2021)</td><td>$83.21</td",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "8643501ad6310b89",
        "value": 83.21,
        "unit": "$",
        "metric_type": "currency",
        "context": ")</td><td>$175.45</td></tr><tr><td>Merck &amp;amp; Co., Inc. (MRK.N)</td><td>E (09/07/2021)</td><td>$83.21</td></tr><tr><td>Organon &amp;amp; Co. (OGN.N)</td><td>E (06/11/2021)</td><td>$9.18</td></tr>",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "d132c6a6ec4c808c",
        "value": 9.18,
        "unit": "$",
        "metric_type": "currency",
        "context": "/2021)</td><td>$83.21</td></tr><tr><td>Organon &amp;amp; Co. (OGN.N)</td><td>E (06/11/2021)</td><td>$9.18</td></tr><tr><td>Pfizer Inc (PFE.N)</td><td>E (07/30/2019)</td><td>$24.60</td></tr><tr><td>Roy",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "49e6746eecb505d7",
        "value": 24.6,
        "unit": "$",
        "metric_type": "currency",
        "context": "<td>E (06/11/2021)</td><td>$9.18</td></tr><tr><td>Pfizer Inc (PFE.N)</td><td>E (07/30/2019)</td><td>$24.60</td></tr><tr><td>Royalty Pharma Plc (RPX.N)</td><td>O (05/16/2025)</td><td>$35.62</td></tr></",
        "provenance": {
          "page": 28
        }
      },
      {
        "num_id": "2fc986c66b702b1c",
        "value": 35.62,
        "unit": "$",
        "metric_type": "currency",
        "context": "/30/2019)</td><td>$24.60</td></tr><tr><td>Royalty Pharma Plc (RPX.N)</td><td>O (05/16/2025)</td><td>$35.62</td></tr></table> Stock Ratings are subject to change. Please see latest research for each co",
        "provenance": {
          "page": 28
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 17,
      "tables_count": 0,
      "numerical_data_count": 78,
      "passages_count": 148,
      "entities_count": 20
    }
  }
}